Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Xilio Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 31 | 34 | +3 |
| Shares | 15.9M | 16.4M | +566.2K (+3.6%) |
| Value | $33.5M | $9.03M | −$24.4M (−73.0%) |
New holders (6)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $811.3K | 0.25% |
| ArrowMark Colorado Holdings LLC | 83,373 | $45.9K | 0.00% |
| Citadel Advisors LLC | 51,419 | $28.3K | 0.00% |
| Millennium Management LLC | 30,351 | $16.7K | 0.00% |
| Virtu Financial LLC | 10,763 | $6.00K | 0.00% |
| Dunhill Financial, LLC | 10,274 | $5.65K | 0.01% |
Sold out (3)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Harvard Management Co Inc | 416,059 | $878.0K |
| Soleus Capital Management, L.P. | 226,941 | $478.8K |
| Dimensional Fund Advisors LP | 26,449 | $55.8K |